Literature DB >> 12751132

Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction.

Tomoaki Nakata1, Takeru Wakabayashi, Michifumi Kyuma, Tohru Takahashi, Akiyoshi Hashimoto, Hitoko Ogata, Kazufumi Tsuchihashi, Kazuaki Shimamoto.   

Abstract

BACKGROUND: Although altered cardiac sympathetic innervation is related to fatal outcome, the mechanisms and prognostic value of an initial cardiac metaiodobenzylguanidine (MIBG) defect are not known. METHODS AND
RESULTS: After quantitative cardiac MIBG imaging, 205 patients with left ventricular ejection fraction <50% were prospectively followed up with a primary end-point of cardiac death for 35 months. In regard to 38 cardiac deaths, consisting of 25 pump failure deaths, 11 sudden deaths, and 2 fatal acute myocardial infarctions, multivariate analysis identified diabetes mellitus as a significant independent predictor as well as reduced cardiac MIBG activity, use of nitrate, and New York Heart Association functional status. Independent of washout kinetics and cardiac function, patients with profound loss of initial MIBG uptake and those with late-phase MIBG activity of 1.74 or less had significantly greater mortality rates than did their counterparts. Initial cardiac MIBG activity closely correlated inversely with annual cardiac death rate.
CONCLUSIONS: An initial cardiac MIBG defect and presence of diabetes mellitus indicate a low probability of long-term survival. The profound loss of initial MIBG activity is likely to be due to structural deficit of sympathetic neurons themselves, rather than accelerated sympathetic function, suggesting that denervation is one of mechanisms of cardiac sympathetic dysfunction leading to lethal clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751132     DOI: 10.1054/jcaf.2003.14

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

Review 1.  Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology.

Authors:  Nagara Tamaki; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 2.  Cardiac metaiodobenzylguanidine imaging and heart failure.

Authors:  Tomoaki Nakata; Akiyoshi Hashimoto; Hirohito Sugawara
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 3.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

4.  Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.

Authors:  Tomoaki Nakata; Takeru Wakabayashi; Michifumi Kyuma; Toru Takahashi; Kazufumi Tsuchihashi; Kazuaki Shimamoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-25       Impact factor: 9.236

5.  Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus.

Authors:  Shigeki Nagamachi; Seigo Fujita; Ryuichi Nishii; Shigemi Futami; Shozo Tamura; Masanari Mizuta; Masamitsu Nakazato; Takeshi Kurose; Hideyuki Wakamatsu
Journal:  J Nucl Cardiol       Date:  2006 Jan-Feb       Impact factor: 5.952

Review 6.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

Review 7.  Molecular imaging in heart failure patients.

Authors:  Nagara Tamaki; Yuji Kuge; Keiichiro Yoshinaga
Journal:  Clin Transl Imaging       Date:  2013-10-09

8.  I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study.

Authors:  Denis Agostini; Hein J Verberne; Wolfgang Burchert; Juhani Knuuti; Pavol Povinec; Gianmario Sambuceti; Mustafa Unlu; Montserrat Estorch; Gopa Banerjee; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 10.057

9.  Prediction of ong-term ardiac vents by 123I-meta-odobenzylguanidine maging after acute yocardial nfarction and eperfusion herapy.

Authors:  Manabu Nakamura; Masahisa Onoguchi; Takayuki Shibutani
Journal:  Asia Ocean J Nucl Med Biol       Date:  2019
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.